ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
PP&E Net
ADC Therapeutics SA
PP&E Net Peer Comparison
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
PP&E Net
$16.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
PP&E Net
CHf6.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
PP&E Net
$305.9m
|
CAGR 3-Years
49%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
PP&E Net
CHf20.6m
|
CAGR 3-Years
57%
|
CAGR 5-Years
26%
|
CAGR 10-Years
5%
|
|
Idorsia Ltd
SIX:IDIA
|
PP&E Net
CHf245.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
PP&E Net
CHf2.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's PP&E Net?
PP&E Net
16.1m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's PP&E Net amounts to 16.1m USD.
What is ADC Therapeutics SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
61%
Over the last year, the PP&E Net growth was 61%. The average annual PP&E Net growth rates for ADC Therapeutics SA have been 50% over the past three years , 61% over the past five years .